A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
This study tests a new drug, SIM0505, for adults with advanced solid tumors. It aims to see if the drug is safe, tolerable, and if it helps fight the cancer. The study is open-label, meaning all participants know they are receiving SIM0505. Eligible participants are adults (18+ years) who have tried other cancer treatments without success and have certain types of tumors. Some of these include ovarian cancer, lung cancer, and kidney cancer. Participants must have a life expectancy of at least 12 weeks and meet other health requirements, like normal organ function. Key Points:
This study tests a new drug, SIM0505, for adults with advanced solid tumors. It aims to see if the drug is safe, tolerable, and if it helps fight the cancer. The study is open-label, meaning all participants know they are receiving SIM0505. Eligible participants are adults (18+ years) who have tried other cancer treatments without success and have certain types of tumors. Some of these include ovarian cancer, lung cancer, and kidney cancer. Participants must have a life expectancy of at least 12 weeks and meet other health requirements, like normal organ function. Key Points:
- The study involves two parts and requires different eligibility criteria for each.
- Participants must use effective birth control and have regular doctor check-ups.
- Some past medical conditions or treatments may exclude participation.
How understandable was the trial content above?
Hard to understand
Easy to understand